SEC Comment Letter 0000000000-24-006981 to Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc.
Date: June 18, 2024 · CIK: 0001835022 · Accession: 0000000000-24-006981
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280235
Letter
United States securities and exchange commission logo June 18, 2024 Howard Berman Chief Executive Officer Coya Therapeutics, Inc. 5850 San Felipe St. Suite 500 Houston, TX 77057 Re:Coya Therapeutics, Inc. Registration Statement on Form S-3 Filed June 14, 2024 File No. 333-280235 Dear Howard Berman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven M. Skolnick, Esq.
Show Raw Text
United States securities and exchange commission logo
June 18, 2024
Howard Berman
Chief Executive Officer
Coya Therapeutics, Inc.
5850 San Felipe St. Suite 500
Houston, TX 77057
Re:Coya Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 14, 2024
File No. 333-280235
Dear Howard Berman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven M. Skolnick, Esq.